BioSpace News Archive

BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.

Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.

Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.

Andelyn Biosciences, a pioneering cell and gene therapy CDMO born out of Nationwide Children’s Hospital, announced the U.S. FDA’s acceptance of its GMP plasmid DNA drug master file, which enables the organization to vertically integrate its clients’ manufacturing process, condensing timelines for developers to begin manufacturing to just three months.

Spago Nanomedical AB announced that interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix is well tolerated and provides clear contrast enhancement in MRI images of solid tumors in the breast, as well as in the pancreas and liver.

ADVANZ PHARMA Corp. Limited and Allecra Therapeutics announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway.

BenevolentAI , a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca.

Electromedical Technologies, Inc., a pioneer in the development and manufacturing of bioelectronic devices, is pleased to issue the following Annual Letter to Shareholders from the Company’s Chief Executive Officer:

Angelini Pharma, an international pharmaceutical company which is part of the privately-owned Angelini Industries, has appointed Rafal Kaminski as its new Chief Scientific Officer.

Imcyse today reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the Company’s lead candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to treat and prevent T1D.